Table 3.
Clinical characteristics according to venous thrombosis findings.
| VT (n = 7) | No VT (n = 80) | |
|---|---|---|
| Age | 70 ± 17.4 | 73 ± 15.9 |
| BMI (kg/m2) | 28.7 ± 5.9 | 27.4 ± 4.3 |
| Time from symptom onset to hospital admission (days) | 18 ± 15.9 | 21 ± 12.8 |
| Time from admission to ultrasound performance (days) | 17 ± 10.1 | 18 ± 11.6 |
| Charlson index | 3.7 ± 3.4 | 4.5 ± 3 |
| Smoker (≥5 pack-years) | 2 (28.6%) | 24 (30%) |
| History of VTE* | 1 (14.3%) | 4 (5%) |
| Chronic anticoagulant therapy | 0 (0%) | 15 (18.7%) |
| ICU admission | 4 (57%) | 22 (27.5%) |
| Length of stay in ICU (days) | 22.5 ± 21.7 | 31 ± 11.8 |
| Clinical severity score | ||
| Mild | 1 (14.3%) | 6 (7.5%) |
| Moderate | 0 (0%) | 26 (32.5%) |
| Sever | 2 (28.6%) | 25 (31.3%) |
| Critical | 4 (57.1%) | 23 (28.8%) |
| Treatment with anti-inflammatory drugs (during hospitalization) | ||
| Steroids | 3 (24.9%) | 45 (56.3%) |
| Tocilizumab | 2 (28.6%) | 20 (25%) |
| Anakinra | 0 | 3 (3.8%) |
| None | 4 (57.1%) | 12 (15%) |
| Any | 3 (42.9%) | 68 (85%) |
| LMWH dose prescribed during hospitalization | ||
| Prophylactic | 3 (42.9%) | 50 (62.5%) |
| Intermediate | 1 (14.3%) | 11 (13.8%) |
| Anticoagulant | 1 (14.3%) | 18 (22.5%) |
| None | 2 (28.6%) | 1 (1.2%) |
| D-dimer (mg/L): median (IQR) | 11.18 (7.38–22.00) | 3.37 (1.20–12.62) |
| Ferritin (ng/mL) | 765 ± 514.8 | 886.9 ± 900.9 |
| CRP (mg/L) | 174 ± 108.4 | 158.5 ± 109.7 |
VT = venous thrombosis; BMI = body mass index; VTE = venous thromboembolism; ICU = intensive care unit; LMWH = low molecular height heparin; CRP = C-reactive protein; IQR = interquartile range.
Quantitative variables are expressed in mean ± standard deviation, except those related to time, which are expressed in median.